{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/","result":{"pageContext":{"chapter":{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids","depth":2,"htmlHeader":"<!-- begin field c366837e-a247-42be-b0f6-b2d18aef214c --><h2>Scenario: Weak opioids</h2><!-- end field c366837e-a247-42be-b0f6-b2d18aef214c -->","summary":"Covers prescribing information on weak opioids, including information on the choice of weak opioid, adverse effects, interactions, safety in pregnancy and breastfeeding, and general advice.","htmlStringContent":"<!-- begin item 036bfca2-c14d-4d93-bde7-38471b73fc8a --><!-- begin field a6e8d0f5-e5b2-426e-9a5a-acd900ad05d6 --><p>From age 3 months onwards.</p><!-- end field a6e8d0f5-e5b2-426e-9a5a-acd900ad05d6 --><!-- end item 036bfca2-c14d-4d93-bde7-38471b73fc8a -->","topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","lastRevised":"Last revised in August 2020","chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","fullItemName":"Management","slug":"management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a9ab7a71-3fdb-5f2f-9a4f-4099557a7004","slug":"choice","fullItemName":"Choice","depth":3,"htmlHeader":"<!-- begin field 5d8bb0bb-e67b-4139-b4d7-b7c335f57e95 --><h3>Which weak opioid should I prescribe for the treatment of mild-to-moderate pain?</h3><!-- end field 5d8bb0bb-e67b-4139-b4d7-b7c335f57e95 -->","summary":null,"htmlStringContent":"<!-- begin item 6fa78cc0-e2fa-447a-97ca-4615a68335cc --><!-- begin field 3434c3b1-52be-4c01-84f7-a4fddd1ab741 --><ul><li><strong>In adults:</strong><ul><li>Prescribe codeine, dihydrocodeine, or tramadol if the person has an inadequate response to paracetamol and/or a nonsteroidal anti-inflammatory drug (such as ibuprofen or naproxen).<ul><li>Tramadol is a Schedule 3 controlled drug and as such is subject to the legal prescription requirements associated with controlled drugs.</li><li>Codeine has to be converted to morphine in the body to achieve an analgesic effect (240 mg of codeine is approximately equivalent to 30 mg of morphine). The capacity to metabolize codeine can vary considerably between people: poor metabolizers may not experience analgesia, and ultrarapid metabolizers may experience toxicity. Use an alternative analgesic in these groups of people.</li></ul></li></ul></li><li><strong>In children:</strong><ul><li>Seek specialist advice if a weak opioid is being considered to treat mild-to-moderate pain.</li></ul></li></ul><!-- end field 3434c3b1-52be-4c01-84f7-a4fddd1ab741 --><!-- end item 6fa78cc0-e2fa-447a-97ca-4615a68335cc -->","subChapters":[{"id":"af25475c-2cb9-5930-933e-b931b6c048fb","slug":"basis-for-recommendation-459","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fbfd2019-96d8-441c-aa90-64e417318770 --><h4>Basis for recommendation</h4><!-- end field fbfd2019-96d8-441c-aa90-64e417318770 -->","summary":null,"htmlStringContent":"<!-- begin item 4599890d-9f61-487f-bf6f-d31377023af2 --><!-- begin field 4e01bf43-7630-40e3-90dc-785bfb5b4332 --><h5>Adults</h5><ul><li>Codeine is licensed for the treatment of mild-to-moderate pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>].</li><li>Dihydrocodeine and tramadol are both licensed for the treatment of moderate-to-severe pain [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>].<ul><li>In 2013, the Advisory Council on the Misuse of Drugs called for tramadol to be reclassified as a controlled drug because it found the number of tramadol-related deaths had almost doubled from 83 in 2008 to 154 in 2011. The government considered these concerns and decided to reclassify tramadol as a Schedule 3 controlled drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Home Office, 2014</a>].</li></ul></li><li>Weak opioids are recommended in the <a data-hyperlink-id=\"a083e7b3-c775-41c4-9d4e-ac120143961b\" href=\"https://www.who.int/cancer/palliative/painladder/en/\">WHO pain ladder</a> for people who have an inadequate response to paracetamol and/or a nonsteroidal anti-inflammatory drug (NSAID) and for people who have an inadequate response to paracetamol but cannot take an NSAID.</li><li>The information on the metabolism of codeine is based on a guideline issued by the Greater Manchester and Eastern Cheshire Strategic Clinical Networks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">GMEC SCN, 2019</a>]. The British National Formulary (BNF) states that codeine is contraindicated in people who are known to be ultrarapid metabolizers of codeine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</li></ul><h5>Children</h5><ul><li>Tramadol and dihydrocodeine tablets are licensed for use in children aged over 12 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>]. However, CKS recommends seeking specialist advice if a weak opioid is being considered to treat mild-to-moderate pain in a child aged younger than 16 years.</li><li>Codeine is contraindicated in children aged under 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>]. <ul><li>Following a review by the European Medicines Agency (EMA), the use of codeine as an analgesic for children and adolescents is now restricted [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">EMA, 2013</a>]. The EMA has advised that it should only be used to relieve acute moderate pain in children aged over 12 years if pain cannot be relieved by other analgesics, such as paracetamol or ibuprofen.</li></ul></li></ul><!-- end field 4e01bf43-7630-40e3-90dc-785bfb5b4332 --><!-- end item 4599890d-9f61-487f-bf6f-d31377023af2 -->","subChapters":[]}]},{"id":"29bea6f0-0121-5aae-837d-e36d6ba8bb6a","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field f15ffbd7-a2a2-46ee-9a2a-f1e7af994f4c --><h3>What are the cautions and contraindications for weak opioids?</h3><!-- end field f15ffbd7-a2a2-46ee-9a2a-f1e7af994f4c -->","summary":null,"htmlStringContent":"<!-- begin item 08d2c857-5c50-40ee-9ae3-af4f71028386 --><!-- begin field 873e9663-f3da-4966-b6e4-0ab164b7d389 --><ul><li><strong>Do not prescribe weak opioids to:</strong><ul><li>People with:<ul><li>Acute respiratory depression — as there is a theoretical risk of further respiratory depression.</li><li>Conditions associated with increased intracranial pressure (such as cerebral cancer or abscess, or benign intracranial hypertension) or a head injury — opioid analgesics interfere with pupillary responses vital for neurological assessment.</li><li>Risk of paralytic ileus — opioids reduce gastric motility.</li><li>Chronic obstructive pulmonary disease — due to the risk of respiratory depression.</li><li>An acute exacerbation of asthma — opioids can aggravate bronchoconstriction as a result of histamine release.</li></ul></li><li>People who are comatose.</li></ul></li><li><strong>In addition:</strong><ul><li><strong>Do not prescribe codeine in:</strong><ul><li>People with liver disease or severe hepatic dysfunction.</li><li>People with conditions where inhibition of peristalsis is to be avoided, where there is a risk of paralytic ileus, where abdominal distension develops, or in acute diarrhoeal conditions (such as acute ulcerative colitis or antibiotic-associated colitis, or diarrhoea caused by poisoning).</li><li>Children under the age of 12 years — because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine.</li><li>Children and young people aged 12–18 years who undergo tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome — due to an increased risk of developing serious and life-threatening adverse reactions.</li><li>Children and young people aged 12–18 years with breathing problems.</li><li>Breastfeeding women — see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#pregnancy-breastfeeding\">Pregnancy and breastfeeding</a> for more information.</li><li>People who are known to be poor or ultrarapid metabolizers of codeine — poor metabolizers may not experience analgesia, and ultrarapid metabolizers may experience toxicity. Use an alternative analgesic in these groups of people.</li></ul></li><li><strong>Do not prescribe tramadol:</strong><ul><li>In acute intoxication with alcohol, hypnotics, analgesics, opioids, or psychotropic drugs.</li><li>In people with uncontrolled epilepsy — seizures have been reported with licensed doses of tramadol, and tramadol may reduce the seizure threshold in people with controlled epilepsy. The risk of seizures is thought to be increased at higher doses of tramadol (for example when the licensed <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#recommended-doses\">upper daily limit</a> is exceeded).</li><li>To children under the age of 12 years.</li><li>For use in narcotic withdrawal treatment.</li></ul></li></ul></li><li><strong>Prescribe weak opioids with caution in:</strong><ul><li>People with:<ul><li>Adrenocortical insufficiency — <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#recommended-doses\">reduced dose</a> is recommended.</li><li>Asthma — avoid during an acute attack.</li><li>Hypotension.</li><li>Hypothyroidism — <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#recommended-doses\">reduced dose</a> is recommended.</li><li>Impaired respiratory function.</li><li>Myasthenia gravis.</li><li>Renal impairment — the effects are increased and prolonged. Where possible, avoid using weak opioids or use a <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#recommended-doses\">reduced dose</a>.</li><li>Hepatic impairment — avoid using weak opioids if possible or start with a low dose and titrate slowly. <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">Adverse effects</a>, such as sedation and constipation, can precipitate hepatic encephalopathy, particularly in people who may decompensate.</li><li>Obstructive or inflammatory bowel disorders (such as ulcerative colitis or Crohn's disease) — opioids reduce gastric motility.</li><li>Diseases of the biliary tract — ureteric or biliary spasm has been reported.</li><li>Prostatic hyperplasia — urinary retention has been reported.</li><li>Shock.</li><li>Urethral stenosis.</li><li>Convulsive disorders.</li></ul></li><li>Debilitated and/or elderly people — as they are more susceptible to <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">adverse effects</a>. Start with a lower dose and titrate up slowly.</li><li>People with a history of drug or substance misuse, alcohol addiction, or a mental health disorder — the risk of drug dependence (addiction), even at therapeutic doses, is increased in these groups of people. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/opioid-dependence/\">Opioid dependence</a> for more information.</li></ul></li><li><strong>In addition, prescribe codeine with caution in people with:</strong><ul><li>Cardiac arrhythmias.</li><li>Gallstones.</li></ul></li></ul><!-- end field 873e9663-f3da-4966-b6e4-0ab164b7d389 --><!-- end item 08d2c857-5c50-40ee-9ae3-af4f71028386 -->","subChapters":[{"id":"987543af-80df-5c64-8118-a0e370e47c9f","slug":"basis-for-recommendation-798","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 77f337e9-e3af-46b1-a91f-90dc2921077f --><h4>Basis for recommendation</h4><!-- end field 77f337e9-e3af-46b1-a91f-90dc2921077f -->","summary":null,"htmlStringContent":"<!-- begin item 798d90b8-b99e-43ab-884d-ef961fc5c977 --><!-- begin field a0533224-ae74-44d1-815f-7329c2f6ef07 --><p>These recommendations are largely based on the manufacturers' Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field a0533224-ae74-44d1-815f-7329c2f6ef07 --><!-- end item 798d90b8-b99e-43ab-884d-ef961fc5c977 -->","subChapters":[]}]},{"id":"ab67fb9c-b7d7-5ab1-8fd9-6dbceb38acb4","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field 6cee2568-0270-4bf0-9459-36f63c8672e5 --><h3>Which dose of weak opioid should I use?</h3><!-- end field 6cee2568-0270-4bf0-9459-36f63c8672e5 -->","summary":null,"htmlStringContent":"<!-- begin item 6231022a-a44a-4875-8938-91631b8b0b00 --><!-- begin field e66aaaf5-9459-4b07-bb9d-f1eedfefc408 --><ul><li><strong>The recommended doses of weak opioids for mild-to-moderate pain in adults are:</strong><ul><li><strong>Codeine</strong> — 30 to 60 mg every 4 hours when necessary (maximum 240 mg in 24 hours).</li><li><strong>Dihydrocodeine</strong> — 30 mg every 4 to 6 hours when necessary (maximum 180 mg in 24 hours).</li><li><strong>Tramadol</strong> — 50 to 100 mg every 4 to 6 hours when necessary (usual maximum 400 mg in 24 hours).</li></ul></li><li><strong>Lower doses of weak opioids (for example codeine 15 mg) are recommended for:</strong><ul><li>Elderly and/or debilitated people — they are more susceptible to the <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">adverse effects</a> of weak opioids. </li><li>People with hypothyroidism and adrenocorticoid insufficiency — opioids can affect endocrine function and lead to hypogonadism and adrenal insufficiency. </li><li>People with moderate-to-severe chronic kidney disease (CKD) — <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">adverse effects</a> may be increased because elimination time is prolonged. Where possible, avoid using weak opioids.</li></ul></li></ul><!-- end field e66aaaf5-9459-4b07-bb9d-f1eedfefc408 --><!-- end item 6231022a-a44a-4875-8938-91631b8b0b00 -->","subChapters":[{"id":"0cc38ff7-3bd6-56f5-852c-a14b3efaf29c","slug":"basis-for-recommendation-c38","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7aa411c6-c8ec-4844-8437-738ce228d2a7 --><h4>Basis for recommendation</h4><!-- end field 7aa411c6-c8ec-4844-8437-738ce228d2a7 -->","summary":null,"htmlStringContent":"<!-- begin item c38e1ab1-c76d-40b9-b020-b88f61302d41 --><!-- begin field 1afbf390-59d3-4b08-aeea-691a4a9d1795 --><p>These recommendations are based on the manufacturers' Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 1afbf390-59d3-4b08-aeea-691a4a9d1795 --><!-- end item c38e1ab1-c76d-40b9-b020-b88f61302d41 -->","subChapters":[]}]},{"id":"844e1f7d-c7cc-582e-bb89-e9dc62660a45","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field df7c5b2c-a237-46fa-afd6-9d6fcc94f276 --><h3>What are the adverse effects of weak opioids?</h3><!-- end field df7c5b2c-a237-46fa-afd6-9d6fcc94f276 -->","summary":null,"htmlStringContent":"<!-- begin item 0b4a8cf6-17ef-4932-a6bb-7e8f281e142c --><!-- begin field 5aea4183-bf3b-46e3-8769-1083f2c3ab0e --><ul><li><strong>Constipation</strong> is a common adverse effect of all weak opioids. <ul><li>If the person needs to take the opioid regularly, a laxative may be required. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/constipation/\">Constipation</a> for prescribing information on laxatives.</li><li>If possible, avoid weak opioids in people with chronic constipation. </li></ul></li><li><strong>Central nervous system adverse effects, </strong>for example sedation, drowsiness, and confusion, are also common.<ul><li>Warn the person to avoid activities where drowsiness may be detrimental (such as driving).</li><li>People taking opioids are allowed to drive in the UK if they are taking no more than the prescribed dose and they feel fit to drive. However, they should avoid driving at the start of treatment and during any dose increases.</li></ul></li><li><strong>Respiratory depression </strong>may commonly occur with high doses.</li><li><strong>Dependence and tolerance</strong> can occur as a result of repeated use. However, psychological dependence rarely occurs when opioids are used therapeutically (for example for pain relief). <ul><li>Over-the-counter analgesics containing codeine or dihydrocodeine should be used for a maximum of 3 days because they can cause dependency and medication overuse headache. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/headache-medication-overuse/\">Headache - medication overuse</a> for more information.</li></ul></li><li><strong>Other possible adverse effects include:</strong><ul><li>Common or very common:<ul><li>Arrhythmias, dry mouth; euphoric mood, flushing, hallucination, headache, hyperhidrosis, hypotension (with high doses), miosis, nausea and vomiting (more common on initiation), palpitations, skin reaction, urinary retention, vertigo, and visual impairment.</li><li>In addition for tramadol — fatigue.</li></ul></li><li>Uncommon:<ul><li>Dysphoria.</li></ul></li><li>Rare or very rare:<ul><li>For tramadol — blurred vision, dyspnoea, epileptiform seizure, and sleep disorders.</li></ul></li><li>Frequency not known:<ul><li>For codeine — altered mood, biliary spasm, decreased appetite, depression, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, dyspnoea, facial oedema, fatigue, fever, hyperglycaemia, hypersensitivity, hypothermia, increased intracranial pressure, lymphadenopathy, malaise, muscle rigidity (with high doses), nightmare, pancreatitis, restlessness, seizure, sexual dysfunction, splenomegaly, ureteral spasm, urinary disorders, and vision disorders.</li><li>For dihydrocodeine — altered mood, dysuria, biliary spasm, bronchospasm, hypothermia, sexual dysfunction, and ureteral spasm.</li><li>For tramadol — anxiety, blood disorders, exacerbation of asthma, hypertension, hypoglycaemia, paraesthesia, syncope, tremor, and urinary disorder.</li></ul></li></ul></li><li><strong>Overuse or misuse of opioid analgesics may result in overdose and/or death. </strong><ul><li>The general symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation, and lack of appetite. In severe cases, this may include symptoms of circulatory and respiratory depression, which may be life threatening.</li><li>Advise the person to only use medicines that are prescribed for them at the dose they have been prescribed and to not give this medicine to anyone else.</li><li>Monitor the person closely for signs of misuse, abuse, or addiction.</li><li>Review the clinical need for analgesic treatment regularly.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/opioid-dependence/\">Opioid dependence</a> for more information.  </li></ul></li></ul><!-- end field 5aea4183-bf3b-46e3-8769-1083f2c3ab0e --><!-- end item 0b4a8cf6-17ef-4932-a6bb-7e8f281e142c -->","subChapters":[{"id":"abb0a1ff-460b-5d01-bae4-f5c205bf0104","slug":"basis-for-recommendation-a91","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f519a320-1af1-4412-ada6-fe9be9c3d3e4 --><h4>Basis for recommendation</h4><!-- end field f519a320-1af1-4412-ada6-fe9be9c3d3e4 -->","summary":null,"htmlStringContent":"<!-- begin item a913204a-6765-48a3-add6-5937978cbffd --><!-- begin field 528ed3c7-a00b-46c9-a772-c26414c4e6c4 --><p>These recommendations are largely based on the manufacturers' Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><ul><li>The information on dependence and tolerance is also based on the Drug Safety Update <em>Over-the-counter painkillers containing codeine or dihydrocodeine </em>published by the Medicines and Healthcare products Regulatory Agency (MHRA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">MHRA, 2009</a>].</li><li>The advice on driving is based on expert opinion in the British Pain Society guideline <em>Opioids for persistent pain: Information for patients</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">British Pain Society, 2010</a>] and the Department for Transport document <em>Guidance for healthcare professionals on drug drivin</em><em>g</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Department for Transport, 2014</a>].</li></ul><!-- end field 528ed3c7-a00b-46c9-a772-c26414c4e6c4 --><!-- end item a913204a-6765-48a3-add6-5937978cbffd -->","subChapters":[]}]},{"id":"c46cda18-e7c0-5abd-bfbb-a4c9c8c80156","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7614d2d4-098a-4c3e-bc70-814f5ca35621 --><h3>What are the key drug interactions with weak opioids and how should I manage them?</h3><!-- end field 7614d2d4-098a-4c3e-bc70-814f5ca35621 -->","summary":null,"htmlStringContent":"<!-- begin item 95135aa9-3213-4257-b67a-567235bce2bf --><!-- begin field e8cdedde-c3c5-4f31-a684-46aa2051b089 --><ul><li><strong>Drug interactions with weak opioids include:</strong><ul><li>Monoamine oxidase inhibitors (MAOIs) — concurrent use with a weak opioid may result in life-threatening interactions on central nervous system (CNS), respiratory, and cardiovascular function. <ul><li>Avoid concurrent use and for 2 weeks after discontinuation of an MAOI.</li></ul></li><li>Other CNS depressants (for example sedatives or hypnotics, phenothiazines, or alcohol) — weak opioids may potentiate the effects of CNS depressants and cause respiratory depression or sedation. <ul><li>Concurrent use should be avoided or done with caution.</li></ul></li><li>Buprenorphine — predicted to increase the risk of opiate withdrawal when given with a weak opioid.<ul><li>Manufacturer makes no recommendation.</li></ul></li></ul></li><li><strong>In addition, for tramadol:</strong><ul><li>Bupropion — predicted to decrease the efficacy of tramadol. <ul><li>Manufacturer makes no recommendation.</li></ul></li><li>Carbamazepine — decreases the concentration of tramadol.<ul><li>During concurrent use the dose of tramadol may need to be increased according to clinical response, but within the maximum allowable dose.</li></ul></li><li>Fluoxetine and paroxetine — predicted to decrease the efficacy of tramadol.<ul><li>Manufacturer makes no recommendation.</li></ul></li><li>Terbinafine — predicted to decrease the efficacy of tramadol.<ul><li>Manufacturer makes no recommendation.</li></ul></li><li>Other serotonergic drugs — concurrent use with other serotonergic drugs (such as antidepressants) can increase the risk of serotonin syndrome. <ul><li>The characteristic symptoms of serotonin syndrome fall into three main areas, although features from each group may not be present: neuromuscular hyperactivity (such as tremor, hyperreflexia, clonus, myoclonus, and rigidity), autonomic dysfunction (tachycardia, blood pressure changes, hyperthermia, diaphoresis, shivering, and diarrhoea), and altered mental state (agitation, confusion, and mania).</li><li>Treatment consists of withdrawal of the serotonergic drug and supportive care; specialist advice should be sought.</li></ul></li><li>Other seizure threshold-lowering drugs — tramadol can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), antipsychotics, and other seizure threshold-lowering drugs (such as bupropion and mirtazapine) to cause convulsions.<ul><li>The manufacturer states that people with epilepsy or those susceptible to seizures should be only treated with tramadol if there are compelling circumstances.</li></ul></li></ul></li><li><strong>See the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"91bc0f7b-d72b-417f-93d9-a98c00d870a8\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"27c10c25-b695-4ce5-b76d-a98c00d87121\">British National Formulary</a> (BNF) for a list of all possible drug interactions with codeine, dihydrocodeine, and tramadol.</strong></li></ul><!-- end field e8cdedde-c3c5-4f31-a684-46aa2051b089 --><!-- end item 95135aa9-3213-4257-b67a-567235bce2bf -->","subChapters":[{"id":"f6df9c65-40d0-5da1-abbf-565b8c013e19","slug":"basis-for-recommendation-6a3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 41133478-ca70-4246-9b84-16b17e884031 --><h4>Basis for recommendation</h4><!-- end field 41133478-ca70-4246-9b84-16b17e884031 -->","summary":null,"htmlStringContent":"<!-- begin item 6a35fad3-62d7-4ddd-8c22-9cc7911faa74 --><!-- begin field 190e369d-eccb-4aa2-be37-80815dfb6f5d --><p>These recommendations are largely based on the manufacturers' Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 190e369d-eccb-4aa2-be37-80815dfb6f5d --><!-- end item 6a35fad3-62d7-4ddd-8c22-9cc7911faa74 -->","subChapters":[]}]},{"id":"7b49eb85-7c75-5a4f-acc7-b90c94d6555e","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field dfd2606d-7881-456e-baac-32db5f562758 --><h3>Can I prescribe weak opioids to a woman who is pregnant or breastfeeding?</h3><!-- end field dfd2606d-7881-456e-baac-32db5f562758 -->","summary":null,"htmlStringContent":"<!-- begin item 24762467-632a-4a21-8a59-c30424676172 --><!-- begin field c3449cec-7b80-47c1-880b-283e963953dd --><h4>Pregnancy</h4><ul><li>Paracetamol is the analgesic of choice during pregnancy.</li><li>If a weak opioid is required, codeine is preferred.<ul><li>Codeine can be used short term in all trimesters of pregnancy. However, the use of codeine near the end of the third trimester may cause neonatal respiratory depression. Long-term use may cause withdrawal symptoms in the baby.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Paracetamol is the analgesic of choice during breastfeeding. </li><li>If a weak opioid is required, tramadol or dihydrocodeine may be used at the lowest effective dose and for the shortest possible duration. </li><li>Regular use of any opioid in a breastfeeding mother beyond 3 days should be under close medical supervision.</li><li>Be aware that:<ul><li>If significant opioid <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">adverse effects</a> develop in the mother, this could suggest the possibility that she is an ultrarapid metabolizer and that the risk of adverse effects in the infant may be increased.</li><li>Advise breastfeeding mothers who are taking weak opioids to stop breastfeeding and seek medical advice if they develop opioid adverse effects.</li></ul></li><li>Seek expert advice if:<ul><li>The infant is pre-term or low birth weight.</li><li>The absorption, distribution, metabolism, or excretion of the weak opioid may be affected by an underlying medical condition in the infant.</li><li>The mother is taking multiple medicines.</li></ul></li></ul><!-- end field c3449cec-7b80-47c1-880b-283e963953dd --><!-- end item 24762467-632a-4a21-8a59-c30424676172 -->","subChapters":[{"id":"f36b9849-ce08-5bb9-a4c3-9c519facef25","slug":"basis-for-recommendation-6e5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c6500e9d-cb6e-403a-9574-c52da22fc4ab --><h4>Basis for recommendation</h4><!-- end field c6500e9d-cb6e-403a-9574-c52da22fc4ab -->","summary":null,"htmlStringContent":"<!-- begin item 6e5ca2f9-4e2a-4994-aff2-75b9bdf6ae45 --><!-- begin field 61fd998b-c7e7-4ec5-bcaf-d2a5ccfe4dc0 --><h5>Pregnancy</h5><ul><li>Codeine<ul><li>The manufacturer of codeine states that caution should be exercised during pregnancy, especially in the first trimester, due to a possible association with respiratory and cardiac malformations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>]. The UK Teratology Information Service (UKTIS) states that although observational studies have found an increase in the risk of fetal malformation with its use during pregnancy, the evidence is inconsistent and codeine may be used in pregnancy if paracetamol has been ineffective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2015</a>].<ul><li>There are theoretical concerns that maternal use of codeine near term may be associated with neonatal respiratory depression. However, the only study that has investigated this adverse event found no increased risk. There are a small number of published case reports of perinatal arterial stroke and neonatal withdrawal in infants of women who used codeine in the weeks before delivery; however, no epidemiological studies have investigated these associations.</li><li>There are no data regarding the risk of spontaneous abortion, intrauterine death, or offspring neurodevelopment following in utero codeine exposure.</li></ul></li></ul></li><li>Dihydrocodeine<ul><li>The UKTIS states that there are no pregnancy safety data specifically for dihydrocodeine; however, risks are expected to be similar to those for codeine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2015</a>].</li></ul></li><li>Tramadol<ul><li>There is inadequate evidence available on the safety of tramadol in human pregnancy. Therefore, the manufacturer does not recommend its use during pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>].</li><li>The UKTIS found little evidence on the use of tramadol during pregnancy and states that if a weak opioid is required during pregnancy, codeine is the drug of choice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKTIS, 2016</a>].</li></ul></li></ul><h5>Breastfeeding</h5><ul><li>Codeine<ul><li>The Medicines and Healthcare products Regulatory Agency (MHRA) advises against the use of codeine during breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">MHRA, 2013</a>], based on a report of a fatal case of morphine toxicity in a breastfed infant following maternal use of codeine.</li></ul></li><li>Dihydrocodeine<ul><li>An evidence-based review published by the UK Medicines Information service (UKMi) found that although there is no published evidence for the safety of dihydrocodeine use during breastfeeding, extensive anecdotal experience supports its safe use. The UKMi advises that until more data are available regarding the metabolism of dihydrocodeine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKMi, 2020</a>]:<ul><li>Use in a breastfeeding mother should be at the lowest effective dose for the shortest duration.</li><li>All breastfed infants should be monitored for opioid adverse effects regardless of the maternal dose, including sedation, breathing difficulties, constipation, poor feeding, and adequate weight gain.</li><li>If significant opioid adverse effects develop in the mother, this could suggest the possibility that she is an ultrarapid metabolizer and that the risk of adverse effects in the infant may be increased.</li></ul></li></ul></li><li>Tramadol<ul><li>There is limited evidence for use of tramadol during breastfeeding. However, these reports have shown low levels in breast milk and there are no published reports of adverse effects in the infants exposed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">UKMi, 2020</a>].</li></ul></li></ul><!-- end field 61fd998b-c7e7-4ec5-bcaf-d2a5ccfe4dc0 --><!-- end item 6e5ca2f9-4e2a-4994-aff2-75b9bdf6ae45 -->","subChapters":[]}]},{"id":"03a8a981-4b84-5c34-b441-f3aaaffeef17","slug":"information-advice","fullItemName":"Information and advice","depth":3,"htmlHeader":"<!-- begin field 51eec6f9-853d-41aa-bc38-ad72232f02ec --><h3>What information and advice should I give to a person receiving weak opioids?</h3><!-- end field 51eec6f9-853d-41aa-bc38-ad72232f02ec -->","summary":null,"htmlStringContent":"<!-- begin item c81496b2-60dd-42d8-bd05-955dfc446e9a --><!-- begin field 15dac339-8de6-41d2-ad4d-434fc11a48e0 --><ul><li><strong>Advise the person:</strong><ul><li>That constipation is a common <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">adverse effect</a> of all weak opioids. <ul><li>A regular laxative is not usually needed for short-term use of weak opioids.</li></ul></li><li>About driving while taking weak opioids:<ul><li>They should not drive if they are drowsy, dizzy, unable to concentrate or make decisions, or if they experience blurred or double vision.</li><li>It is now an offence to drive if they have more than a specified amount of opioid in their body whether driving is impaired or not. It may be helpful for the person to keep evidence (such as their repeat prescription) in the car to show that they are taking an opioid in accordance with medical advice.</li></ul></li><li>That overuse or misuse of opioid analgesics may result in <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">overdose</a> and/or death. Advise the person:<ul><li>To only use medicines that are prescribed for them at the dose they have been prescribed and to not give this medicine to anyone else.</li><li>That weak opioids purchased over-the-counter (OTC) should only be used for up to 3 days before seeking medical advice.</li></ul></li></ul></li><li><strong>Provide written information on weak opioids and pain management.</strong><ul><li>The British Pain Society leaflet <a href=\"https://www.britishpainsociety.org/static/uploads/resources/files/patient_pub_otc.pdf\" data-hyperlink-id=\"117e9632-6c21-4c3b-906d-ac0a01370395\">Managing your pain effectively using “Over the Counter” (OTC) Medicines</a> discusses the short- and long-term use of OTC analgesics and their associated adverse effects.</li><li>The NHS website (<a href=\"https://www.nhs.uk/\" data-hyperlink-id=\"ce42e858-f50b-454c-9ef2-ac0a013703a4\">www.nhs.uk</a>) has information on <a href=\"https://www.nhs.uk/medicines/codeine/\" data-hyperlink-id=\"779cd772-5b4d-4ed2-a3df-ac0a013703d0\">Codeine</a>, <a href=\"https://www.nhs.uk/medicines/dihydrocodeine/\" data-hyperlink-id=\"2048be57-847c-4271-ba65-ac1a01561f02\">Dihydrocodeine</a>, and <a href=\"https://www.nhs.uk/medicines/tramadol/\" data-hyperlink-id=\"26af583f-c102-4d49-9baa-ac0a013703c0\">Tramadol</a>.</li></ul></li></ul><!-- end field 15dac339-8de6-41d2-ad4d-434fc11a48e0 --><!-- end item c81496b2-60dd-42d8-bd05-955dfc446e9a -->","subChapters":[{"id":"1ecf37c7-7d23-5ed2-85e2-430f8af81a2c","slug":"basis-for-recommendation-0a1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d358b8cc-a086-43c8-bb55-4d99766d394a --><h4>Basis for recommendation</h4><!-- end field d358b8cc-a086-43c8-bb55-4d99766d394a -->","summary":null,"htmlStringContent":"<!-- begin item 0a10d0d5-6dd1-4215-bf87-76ad03a1f799 --><!-- begin field 8f333aa3-898e-41a3-959f-65e05ecac6a6 --><p>These recommendations are largely based on what CKS considers to be good clinical practice. </p><h5>Advice on driving</h5><ul><li>The recommendations on driving are based on expert opinion from the British Pain Society guideline <em>Opioids for persistent pain </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">British Pain Society, 2010</a>]<em> </em>and the Department for Transport document <em>Guidance for healthcare professionals on drug driving</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Department for Transport, 2014</a>]. <ul><li>In March 2015, roadside drug screening tests were introduced in the UK. These test the saliva for drugs that impair driving, such as opioids.</li><li>People with a positive roadside drug test for opioids may be required to provide a blood sample to measure the amount of opioid in their body.</li><li>Provided driving is not impaired, people found to have more than the specified amount of opioid in their body but are taking the medicine on the advice of a GP or pharmacist, or in accordance with the patient information leaflet of an opioid that was bought over-the-counter will be able to raise a 'statutory defence' to avoid prosecution.</li></ul></li></ul><!-- end field 8f333aa3-898e-41a3-959f-65e05ecac6a6 --><!-- end item 0a10d0d5-6dd1-4215-bf87-76ad03a1f799 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}